AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

672.660

-3.703-0.55%

Number of Gainers:7

Number of Losers:13

Number of Flat:23

PE:- -

High:685.239

Open:680.163

Low:670.162

Close:676.364

Volume:28.24M

Turnover:54.70M

Market Cap:96.67B

Float Cap:93.56B

Loading ...

Learn Why The Bull Case For CSL (ASX:CSL) Could Change Following Rare Disease Drug Partnership

Simply Wall St.

CSL's Licensing Deal for Lixudebart Signals Current R&D Philosophy

Jefferies Raise Price Target on Australia's CSL After Alentis Licensing Deal

Asia Morning Call-Global Markets

3 US Dividend Stocks For Investors Seeking Reliable Income In Higher Rate Markets

Simply Wall St.

Swiss Stocks - Factors to Watch on October 5

Australia's Imugene Rises on Fresh Responses in Blood Cancer Drug Trial

Dimerix Says First Patient Completes Four Years in Clinical Program for Kidney Disease Drug Candidate; Shares Rise 7%

MT Newswires Live

Australian Shares Rise as Commodity-Linked Stocks Advance

ASX Preview: Australian Shares to Rise as Oil Climbs on Saudi Attacks; CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug

MT Newswires Live

Immutep Says Pete Meyers Resigns as Deputy Chairman and Non-Executive Director

Immutep - Pete Meyers Resigns as Non-Executive Director and Deputy Chairman Effective Oct 2, 2026

THOMSON REUTERS

Immutep Ltd-Resignation of Non-Executive Director

THOMSON REUTERS

CSL Enters Global Lixudebart Partnership with Alentis, Pays Us$355 Million Upfront

CSL and Alentis Announce Global Partnership to Develop and Commercialise Lixudebart for Rare Kidney and Liver Diseases

THOMSON REUTERS

Australia's CSL Strikes Kidney, Liver Disease Drug Deal Worth up to $1.6 Billion

To Pay Alentis $355 Mln Upfront and up to $1.2 Bln in Milestones

THOMSON REUTERS

To Fully Fund Phase 2 and Phase 3 Trials for Lixudebart

THOMSON REUTERS

CSL Limited-CSL Enters Exclusive Agreement with Alentis Therapeutics

THOMSON REUTERS

Enters Agreement with Alentis to Co-Develop and Co-Promote Lixudebart

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK7508/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":672.66046,"timestamp":1791425886791,"preClose":676.3637,"halted":0,"volume":28241523,"delay":0,"changeRate":-0.005475,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-3.703247,"latestTime":"10-08 13:18:12 AEDT","open":680.1626,"high":685.2389,"low":670.1617,"amount":54703575,"amplitude":0.022292,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791435600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1791414000000,1791435600000]],"turnoverRate":0.001123,"increases":9,"decrements":13,"flats":20,"marketCap":96674792107.25,"floatMarketCap":93564147379.625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":685.2389,"amplitude":0.022292,"preClose":676.3637,"low":670.1617,"latestPrice":672.66046,"volume":28241523,"delay":0,"open":680.1626,"prevYearClose":644.3692,"prevWeekClose":654.21,"prevMonthClose":689.549,"prevQuarterClose":689.549,"fiveDayClose":666.631,"twentyDayClose":646.103,"sixtyDayClose":495.646,"secType":"PLATE","market":"AU","turnoverRate":0.001123,"marketCap":96674792107.25,"floatMarketCap":93564147379.625,"timestamp":1791425886791,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":7,"down":13,"flat":23},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673055216","title":"Learn Why The Bull Case For CSL (ASX:CSL) Could Change Following Rare Disease Drug Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2673055216","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673055216?lang=en_us&edition=fundamental","pubTime":"2026-10-06 17:19","pubTimestamp":1791278359,"startTime":"0","endTime":"0","summary":"CSL and Alentis Therapeutics recently agreed an exclusive global collaboration to co-develop and co-promote lixudebart for rare kidney and liver diseases, with CSL funding Phase 2 and Phase 3 programs and Alentis eligible for a US$355 million upfront payment plus up to US$1.2b in milestones and shared profits.\nThe structure of the lixudebart deal, with CSL taking on full development funding and a 55% share of global profits, signals a clear commitment to expand its nephrology and rare...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/learn-why-the-bull-case-for-csl-asxcsl-could-change-followin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/learn-why-the-bull-case-for-csl-asxcsl-could-change-followin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","CSL.AU","BK7511","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673824820","title":"CSL's Licensing Deal for Lixudebart Signals Current R&D Philosophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2673824820","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673824820?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:50","pubTimestamp":1791237000,"startTime":"0","endTime":"0","summary":"2149 GMT - CSL's deal with Alentis Therapeutics to jointly develop and promote a rare kidney and liver disease treatment is emblematic of its current research and development philosophy, suggests Jeff","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7067","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673708453","title":"Jefferies Raise Price Target on Australia's CSL After Alentis Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2673708453","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673708453?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:33","pubTimestamp":1791232419,"startTime":"0","endTime":"0","summary":"BUZZ-Jefferies raise price target on Australia's CSL after Alentis licensing deal** Jefferies raise CSL'sCSL.AXprice target to A$161.50 from A$146.50 after companylicensedlixudebart, a Phase 2 anti-fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R1C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7067","CSL.AU","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673089924","title":"Asia Morning Call-Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2673089924","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673089924?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:30","pubTimestamp":1791225047,"startTime":"0","endTime":"0","summary":"Asia Morning Call-Global MarketsOct 6 (Reuters)-Stock MarketsNet ChngStock MarketsNet ChngS&P/ASX 200**8,686.4073.50NZX 50**13,699.0218.53DJIA51,310.49139.86NIKKEI**69,946.41,637.40Nasdaq27,437.26-25.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R15R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7067","CSL.AU","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673089740","title":"3 US Dividend Stocks For Investors Seeking Reliable Income In Higher Rate Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2673089740","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673089740?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:22","pubTimestamp":1791224560,"startTime":"0","endTime":"0","summary":"Higher rates, sticky inflation risk and heavy AI spending have pulled investors in different directions, yet one theme keeps resurfacing. Reliable dividends from financially solid companies suddenly look less boring and more like ballast. When cash yields compete with equities, income streams backed by strong balance sheets can matter a lot more. This article walks through three high-quality dividend stocks exposed to these cross currents and explains why each one merits a closer look.\nThe...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/269231-card/1789128729799","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/269231-card/1789128729799"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-emr/emerson-electric/news/3-us-dividend-stocks-for-investors-seeking-reliable-income-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-emr/emerson-electric/news/3-us-dividend-stocks-for-investors-seeking-reliable-income-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0054578231.USD","SG9999003800.SGD","CSL","BK7067","BK4086","IE00BVYPNV92.GBP","BK4543","SG9999011175.SGD","BK7508","LU0511384066.AUD","CSL.AU","ISBC","LU0069063385.USD","LU0472753341.HKD","LU0557290698.USD","LU0728928796.USD","IE00BDGV0183.EUR","BK4585","BK4096","LU0289739343.SGD","BK4533","SGXZ23171101.USD","SG9999004303.SGD","IE00B3PB1722.GBP","BK4149","OSK","IE00B42XCP33.USD","BK4211","EMR.AU","BK7511","LU0057025933.USD","LU2355687059.USD","IE00BVYPNW00.USD","LU2211817866.USD","LU0289961442.SGD","BK4588","BK7104","IE00BGHQF631.EUR","LU1169590202.USD","BK7501","EMR","LU1169589451.USD","BK4597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673777897","title":"Swiss Stocks - Factors to Watch on October 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2673777897","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673777897?lang=en_us&edition=fundamental","pubTime":"2026-10-05 13:08","pubTimestamp":1791176909,"startTime":"0","endTime":"0","summary":"Swiss stocks - Factors to watch on October 5ZURICH/GDANSK, Oct 5 (Reuters)-Here are some of the main factors that may affect Swiss stocks on Monday:NESTLENEST.NSA sample of Nestle's low-fat dairy whit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL8N45O0M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7511","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673172772","title":"Australia's Imugene Rises on Fresh Responses in Blood Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673172772","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673172772?lang=en_us&edition=fundamental","pubTime":"2026-10-05 12:24","pubTimestamp":1791174282,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Imugene rises on fresh responses in blood cancer drug trial** Shares of Australia's Imugene LimitedIMU.AXrise as much as 35.1% to A$0.05, their highest level since September 17** Stock on track for its biggest intraday pct rise since July 1, if current trend holds** Clinical-stage cell therapy coreports two additionalpatient responses in Phase 1b trial of blood cancer therapy azer-cel** Patient responses included one complete response in mantle cell lymphoma and one partial response in chronic lymphocytic leukemia** All four patients had previously failed BTK inhibitor therapy - a common class of blood-cancer drug** Says therapy has shown 75% overall response rate across 55 patients evaluated in the study** Stock down nearly 88% YTD, including session's moves","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R06A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMU.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673774180","title":"Dimerix Says First Patient Completes Four Years in Clinical Program for Kidney Disease Drug Candidate; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673774180","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673774180?lang=en_us&edition=fundamental","pubTime":"2026-10-05 11:13","pubTimestamp":1791170020,"startTime":"0","endTime":"0","summary":"Dimerix  said the first patient successfully completed two years in an open label extension study of DMX-200 for the potential treatment of focal segmental glomerulosclerosis, a life-threatening kidney disease, in addition to two years in the Action3 phase 3 trial, according to a Monday filing with the Australian bourse.The open label extension study allows patients who complete a phase three clinical trial to receive DMX-200 for up to two years regardless of whether they received DMX-200 or placebo during the blinded phase of the trial.The phase three trial remains ongoing with the adult group fully recruited, and patients who complete the open label extension study will be offered continued access to DMX-200 once ethics approval for a post-trial-access scheme is obtained, Dimerix said.It added that more than 90% of eligible patients who completed the phase three trial have elected to continue into the two-year open label study, data from which could support future regulatory and comm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7501","DMX","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673779443","title":"Australian Shares Rise as Commodity-Linked Stocks Advance","url":"https://stock-news.laohu8.com/highlight/detail?id=2673779443","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673779443?lang=en_us&edition=fundamental","pubTime":"2026-10-05 08:45","pubTimestamp":1791161131,"startTime":"0","endTime":"0","summary":"Australian shares rise as commodity-linked stocks advanceOct 5 (Reuters)-Australian shares rose on Monday, supported by gains in mining, financial and energy stocks, while investors continued to asses","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R003:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0955623706.USD","BK7095","IE0034235071.USD","LU0171293334.USD","LU1046248800.SGD","LU1078025761.USD","LU0654597011.USD","BK7142","BK7508","LU0345781412.USD","BK5111","CSL.AU","LU0971552673.USD","BK7067","BK7507","IE00BQJZX424.USD","LU0572939691.SGD","LU0788109121.HKD","LU2463526074.USD","RIO.UK","LU1302929846.USD","BK7503","XRO.AU","LU0161305163.EUR","LU1430597077.USD","WDS.AU","LU0266512127.USD","LU0898667661.SGD","BK7135","LU0971552830.HKD","LU1023059493.AUD","BHP.AU","LU1481600234.SGD","LU0330918003.SGD","WBC.AU","BK7501","IE00BWDBJ516.SGD","LU1309081286.SGD","LU0266512473.USD","LU0612318385.USD","LU0955669360.SGD","RIO.AU","LU0630314457.HKD","LU1064927863.SGD","STO.AU","BK7511","LU0505663152.USD","LU0264606111.USD","SG9999001143.SGD","LU0345777659.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776492","title":"ASX Preview: Australian Shares to Rise as Oil Climbs on Saudi Attacks; CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776492","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776492?lang=en_us&edition=fundamental","pubTime":"2026-10-05 07:07","pubTimestamp":1791155252,"startTime":"0","endTime":"0","summary":"Australian shares are poised to rise on Monday after oil prices climbed as attacks claimed by Yemen's Iran-backed Houthis on Saudi Aramco sites raised concerns about potential disruptions to crude production.Oil prices were also supported after the Organization of the Petroleum Exporting Countries decided to keep its November output targets unchanged, limiting expectations for additional supply and helping keep Brent crude above $100 a barrel amid the Iran war.On Oct. 2, the S&P 500, the Nasdaq Composite, and the Dow Jones Industrial Average rose 0.7%, 1.2%, and 0.5%, respectively.In the macroeconomy, Australia's private-sector growth slowed in September as weaker new business weighed on services activity, prompting a resumption of job cuts while inflationary pressures intensified, according to a monthly survey by S&P Global released Monday.In corporate news, CSL  entered a partnership with Alentis Therapeutics to co-develop and co-promote lixudebart, a potential first-in-class therapy","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IIGF.AU","QRE.AU","STW.AU","IMLC.AU","BEAR.AU","BBOZ.AU","BK4139","OZR.AU","E200.AU","VAS.AU","EIGA.AU","BK7067","BK7508","BK4007","OZF.AU","BK4539","CMM.AU","GEAR.AU","GIVE.AU","ZYAU.AU","LENZ","QFN.AU","XKO.AU","IOZ.AU","BK7511","BK7501","CSL.AU","VAP.AU","BK7104","SLF.AU","XJO.AU","IISV.AU","XAO.AU","DACE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673377697","title":"Immutep Says Pete Meyers Resigns as Deputy Chairman and Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2673377697","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673377697?lang=en_us&edition=fundamental","pubTime":"2026-10-05 06:42","pubTimestamp":1791153759,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Says Pete Meyers Resigns as Deputy Chairman and Non-Executive DirectorOct 5 (Reuters)-Immutep LtdIMM.AX:RESIGNATION OF NON-EXECUTIVE DIRECTORPETE MEYERS RESIGNS AS NON-EXECUTIVE DIRECTOR AND DEPUTY CHAIRMAN EFFECTIVE OCT 2, 2026Further company coverage:IMM.AX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE75JFZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776981","title":"Immutep - Pete Meyers Resigns as Non-Executive Director and Deputy Chairman Effective Oct 2, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776981","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776981?lang=en_us&edition=fundamental","pubTime":"2026-10-05 06:37","pubTimestamp":1791153477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE75JFZJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673677698","title":"Immutep Ltd-Resignation of Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2673677698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673677698?lang=en_us&edition=fundamental","pubTime":"2026-10-05 06:37","pubTimestamp":1791153477,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE75JFZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673768577","title":"CSL Enters Global Lixudebart Partnership with Alentis, Pays Us$355 Million Upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2673768577","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673768577?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:42","pubTimestamp":1791150175,"startTime":"0","endTime":"0","summary":"CSL enters global lixudebart partnership with Alentis, pays US$355 million upfrontCSL entered an exclusive global collaboration with Alentis Therapeutics to co-develop, co-promote lixudebart for rare ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nNDL9fTHVp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776854","title":"CSL and Alentis Announce Global Partnership to Develop and Commercialise Lixudebart for Rare Kidney and Liver Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776854","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776854?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:42","pubTimestamp":1791150151,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUABRZMKD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7511","BK7067","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673750477","title":"Australia's CSL Strikes Kidney, Liver Disease Drug Deal Worth up to $1.6 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2673750477","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673750477?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:37","pubTimestamp":1791149849,"startTime":"0","endTime":"0","summary":"Australia's CSL strikes kidney, liver disease drug deal worth up to $1.6 billionOct 5 -Australia's CSLCSL.AXsaid on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion before development funding.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nL1N45Q05Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","CSL.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775745","title":"To Pay Alentis $355 Mln Upfront and up to $1.2 Bln in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775745?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775723","title":"To Fully Fund Phase 2 and Phase 3 Trials for Lixudebart","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775723","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775723?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775717","title":"CSL Limited-CSL Enters Exclusive Agreement with Alentis Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775717?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775710","title":"Enters Agreement with Alentis to Co-Develop and Co-Promote Lixudebart","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775710?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7511","BK7067","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":89,"code":"91000000","status":"200"}]}}